Infiltrating T-cell Markers in Cervical Carcinogenesis: a Systematic Review and Meta-analysis

Overview

Journal Br J Cancer

Specialty Oncology

Date 2020 Dec 1

PMID 33257839

Citations 30

Authors

Tamara R Litwin

Sarah R Irvin

Rebecca L Chornock

Vikrant V Sahasrabuddhe

Margaret Stanley

Nicolas Wentzensen

Affiliations

Soon will be listed here.

Abstract

Background: The host adaptive immune response helps determine which cervical HPV infections persist and progress to precancer and cancer, and systematic characterisation of T-cell infiltration would help inform key steps in cervical carcinogenesis.

Methods: A systematic review and meta-analysis were conducted of infiltrating T-cells in normal cervix, low-grade lesions, high-grade lesions, and invasive cancers including epithelial, stromal, and total tissue and the following markers: CD3, CD4, CD8, FoxP3, CD25, and the CD4:CD8 ratio. An additional qualitative review summarised longitudinal data on associations between infiltrating T-cells and cervical disease persistence, regression, progression, or prognosis.

Results: There were fewer CD3+, CD4+, and CD8+ cells in cervical lesions and more cells in cancers compared to normal epithelium. FoxP3 and CD25+ regulatory T-cell infiltration is high in persistent and precancerous lesions, and longitudinal data show improved outcomes with lower regulatory T-cell levels.

Conclusions: Successful immune evasion may reduce T-cell infiltration in HPV infected and precancerous epithelium, while invasive cancers are highly immunogenic, and regulatory T-cell infiltration increases with cervical disease progression. Understanding these factors may have prognostic value and could aid in novel treatment development and clinical guidelines, but published data are highly heterogeneous and leave important gaps to be filled by future studies.

Citing Articles

Leukocyte-specific protein 1 is associated with the stage and tumor immune infiltration of cervical cancer.

Xu D, Zhou X, Min S, Zhang Y, Zhu X, Qiao K Sci Rep. 2025; 15(1):7566.

PMID: 40038352 PMC: 11880245. DOI: 10.1038/s41598-025-91066-0.

Gene expression levels associated with impaired immune response and increased proliferation could serve as biomarkers for women following cervical cancer screening programmes.

Ovestad I, Dalen I, Soreng K, Akbari S, Lapin M, Janssen E Front Immunol. 2024; 15:1507193.

PMID: 39712018 PMC: 11659148. DOI: 10.3389/fimmu.2024.1507193.

Analysis of the progression of cervical cancer in a low-and-middle-income country: From pre-malignancy to invasive disease.

Robinson E, Rodriguez I, Argueta V, Xie Y, Lou H, Milano R Tumour Virus Res. 2024; 19():200299.

PMID: 39672307 PMC: 11729683. DOI: 10.1016/j.tvr.2024.200299.

Analysis of miR-497/195 cluster identifies new therapeutic targets in cervical cancer.

Karunakara S, Eswaran S, Mallya S, Suresh P, Chakrabarty S, Kabekkodu S BMC Res Notes. 2024; 17(1):217.

PMID: 39095857 PMC: 11297691. DOI: 10.1186/s13104-024-06876-8.

The Micro-Immunotherapy Medicine 2LPAPI Displays Immune-Modulatory Effects in a Model of Human Papillomavirus Type-16 L1-Protein Capsid-Treated Human Peripheral Blood Mononuclear Cells and Antiproliferative Effects in a Model of Cervical Cancer Cells.

Jacques C, Marchand F, Chatelais M, Albinet V, Coustal C, Floris I Cancers (Basel). 2024; 16(7).

PMID: 38611099 PMC: 11010933. DOI: 10.3390/cancers16071421.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Landy R, Pesola F, Castanon A, Sasieni P . Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case-control study. Br J Cancer. 2016; 115(9):1140-1146. PMC: 5117785. DOI: 10.1038/bjc.2016.290. View

Bosch F, Manos M, Munoz N, Sherman M, Jansen A, Peto J . Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995; 87(11):796-802. DOI: 10.1093/jnci/87.11.796. View

Schiffman M, Bauer H, Hoover R, Glass A, Cadell D, Rush B . Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst. 1993; 85(12):958-64. DOI: 10.1093/jnci/85.12.958. View

Ho G, Bierman R, Beardsley L, Chang C, Burk R . Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998; 338(7):423-8. DOI: 10.1056/NEJM199802123380703. View

Castle P, Rodriguez A, Burk R, Herrero R, Wacholder S, Hildesheim A . Long-term persistence of prevalently detected human papillomavirus infections in the absence of detectable cervical precancer and cancer. J Infect Dis. 2011; 203(6):814-22. PMC: 3071125. DOI: 10.1093/infdis/jiq116. View

McCredie M, Sharples K, Paul C, Baranyai J, Medley G, Jones R . Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008; 9(5):425-34. DOI: 10.1016/S1470-2045(08)70103-7. View

Schiffman M, Doorbar J, Wentzensen N, de Sanjose S, Fakhry C, Monk B . Carcinogenic human papillomavirus infection. Nat Rev Dis Primers. 2016; 2:16086. DOI: 10.1038/nrdp.2016.86. View

van der Burg S, de Jong A, Welters M, Offringa R, Melief C . The status of HPV16-specific T-cell reactivity in health and disease as a guide to HPV vaccine development. Virus Res. 2002; 89(2):275-84. DOI: 10.1016/s0168-1702(02)00196-x. View

10.

Stanley M . Epithelial cell responses to infection with human papillomavirus. Clin Microbiol Rev. 2012; 25(2):215-22. PMC: 3346303. DOI: 10.1128/CMR.05028-11. View

11.

Stanley M, Pinto L, Trimble C . Human papillomavirus vaccines--immune responses. Vaccine. 2012; 30 Suppl 5:F83-7. DOI: 10.1016/j.vaccine.2012.04.106. View

12.

Corthay A . How do regulatory T cells work?. Scand J Immunol. 2009; 70(4):326-36. PMC: 2784904. DOI: 10.1111/j.1365-3083.2009.02308.x. View

13.

Dekkers O, Vandenbroucke J, Cevallos M, Renehan A, Altman D, Egger M . COSMOS-E: Guidance on conducting systematic reviews and meta-analyses of observational studies of etiology. PLoS Med. 2019; 16(2):e1002742. PMC: 6383865. DOI: 10.1371/journal.pmed.1002742. View

14.

Whiting P, Rutjes A, Westwood M, Mallett S, Deeks J, Reitsma J . QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155(8):529-36. DOI: 10.7326/0003-4819-155-8-201110180-00009. View

15.

Wan X, Wang W, Liu J, Tong T . Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014; 14:135. PMC: 4383202. DOI: 10.1186/1471-2288-14-135. View

16.

Walboomers J, Jacobs M, Manos M, Bosch F, Kummer J, Shah K . Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189(1):12-9. DOI: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F. View

17.

Abdulhaqq S, Zorrilla C, Kang G, Yin X, Tamayo V, Seaton K . HIV-1-negative female sex workers sustain high cervical IFNɛ, low immune activation, and low expression of HIV-1-required host genes. Mucosal Immunol. 2015; 9(4):1027-38. PMC: 4864149. DOI: 10.1038/mi.2015.116. View

18.

Adurthi S, Krishna S, Mukherjee G, Bafna U, Devi U, Jayshree R . Regulatory T cells in a spectrum of HPV-induced cervical lesions: cervicitis, cervical intraepithelial neoplasia and squamous cell carcinoma. Am J Reprod Immunol. 2008; 60(1):55-65. DOI: 10.1111/j.1600-0897.2008.00590.x. View

19.

Ahmed S, Johnson M, Kitchen V, REID W, Poulter L . Immunity in the female lower genital tract and the impact of HIV infection. Scand J Immunol. 2001; 54(1-2):225-38. DOI: 10.1046/j.1365-3083.2001.00927.x. View

20.

Giannini S, Jacobs N, Moutschen M, Doyen J, Boniver J, Delvenne P . Correlation of T-helper secretory differentiation and types of antigen-presenting cells in squamous intraepithelial lesions of the uterine cervix. J Pathol. 1998; 184(3):283-90. DOI: 10.1002/(SICI)1096-9896(199803)184:3<283::AID-PATH25>3.0.CO;2-K. View